- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
A promotional letter for Melatonin 1mg/ml Oral Solution cited general CCG/RPS guidance and “data on file” in a way that implied product-specific…
A subcontracted media advisor altered and distributed an unauthorised Pradaxa press release that appeared to be from Lifeblood and misused quotations. The…
Consumers International alleged Lilly’s 40over40 ED campaign promoted Cialis to the public. The Panel applied earlier findings: TV ad not promotional, but…
A freelance medical writer challenged Ferinject materials used at a renal meeting. The Panel found misleading dosing presentation and misleading CosmoFer comparisons,…
An anaesthetist complained that a corporate-style MS advertisement in The Economist promoted a prescription-only medicine to the public and raised unfounded hopes.…
Roche challenged two GSK corporate press releases about lapatinib (Tykerb/Tyverb). The Panel ruled one release misleading on adverse events (risk–benefit not fairly…
AstraZeneca challenged a Novartis UK press release headline implying an overall survival benefit for Femara vs tamoxifen. The Panel ruled the headline…
Roche’s Bondronat hospital detail aid was ruled misleading for “innovative” branding, renal safety wording, implied infusion-time comparisons, small-sample resource claims and ASCO…
Complaint said Ezetrol ad implying “New NICE” guidance was misleading vs NICE lipid guideline. Panel found headline clearly referred to NICE TA132…
Roche challenged Novartis’ Zometa congress exhibition panel. Most allegations were not upheld, but the Panel ruled the adapted Forest plot was misleading…
Ferring admitted its PR agency sent uncertified, edited Firmagon copy to a patient organisation. The website content omitted safety info, exaggerated competitor…
Anonymous complaint questioned Takeda’s funding of third‑party diabetes “One Stop Shops” (credentials, independence, prescribing influence). Panel found no evidence of inducement or…
AstraZeneca admitted Nexium 40mg materials implied use for unresolved GORD generally, without making clear 40mg required a diagnosis of erosive reflux oesophagitis…
Pfizer’s Champix leavepiece and GP ad were ruled misleading: key study limitations were relegated to footnotes, NRT comparator was unclear, observational NHS…
A doctor complained a psoriasis journal ad used sexual imagery (woman in underwear in a supermarket). The Panel found it relevant to…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.